TOUYUN BIOTECH (01332) Reports Interim Results with Shareholders' Attributable Profit of HK$11.243 Million, Turning Profitable Year-on-Year
Stock News
Aug 22
TOUYUN BIOTECH (01332) announced its interim results for the six months ended June 30, 2025. The group recorded revenue from sales of goods and services of HK$36.581 million, representing a decrease of 20.82% year-on-year. The profit attributable to owners of the company reached HK$11.243 million, compared to a loss of HK$47.969 million in the same period last year. Earnings per share stood at HK$0.4 cents. According to the announcement, the profit was primarily attributed to increased fair value gains on financial assets measured at fair value through profit or loss.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.